According to Tebao Biotech's announcement, Tonghua Dongbao Pharmaceutical Co., Ltd., a shareholder holding 5% or more of the company's shares, promised not to reduce its direct holdings of the company's shares within 2 years from October 22, 2026, and that shares increased during the commitment period due to the company's bonus shares, share capital transfer, and allotment of shares will also abide by this promise. As of the disclosure date, Tonghua Dongbao directly held 42.125 million shares of the company, with a shareholding ratio of 10.29%.

According to Tebao Biotech's announcement, Tonghua Dongbao Pharmaceutical Co., Ltd., a shareholder holding 5% or more of the company's shares, promised not to reduce its direct holdings of the company's shares within 2 years from October 22, 2026, and that shares increased during the commitment period due to the company's bonus shares, share capital transfer, and allotment of shares will also abide by this promise. As of the disclosure date, Tonghua Dongbao directly held 42.125 million shares of the company, with a shareholding ratio of 10.29%.